Shamrock Pharma Group positions itself as the right API partner in India, for APIs, intermediates and carbapenems, having acquired ownership of 4 manufacturing facilities, 3 R&D labs and one pilot plant dedicated to CRAMS manufacturing and APIs/intermediates. The group recently acquired Unimark Remedies and carbapenem facilities spanning from basic stage to sterile injectable vials, and is seeking marketing network partners for exclusive marketing of its APIs.

Chưa có bình luận nào.
Để lại đánh giá & nhận xét